GENEVA--(BUSINESS WIRE)--Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the appointment of health-care industry veterans Jan H. Egberts, M.D. and Michael J. Dormer, to new chairman of the board and board director, respectively. Representing several decades of senior management experience at industry-leading medical device and pharmaceutical companies, the two join Endosense as it pursues the European commercialization and U.S. Premarket Approval (PMA) clinical study of the company’s proprietary force-sensing ablation catheter, the TactiCath®.
